Xin Ma

Xin Ma

Auto-generated profile, based on publicly available information

Xin Ma

Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHarrison A. Clarke
Harrison A. Clarke
XMXin Ma
Xin Ma
CSCameron J. Shedlock
Cameron J. Shedlock
TMTerrymar Medina
Terrymar Medina
THTara R. Hawkinson
Tara R. Hawkinson
RSramon sun
ramon sun
Metabolites, lipids, and glycans are fundamental but interconnected classes of biomolecules that form the basis of the metabolic network. These molecules are dynamically channeled through multiple pathways that govern cellular physiology and pathology. Here, we present a framework for the simultaneous spatial analysis of the metabolome, lipidome, and glycome from a single tissue section using mass spectrometry imaging. This workflow integrates a computational platform, the Spatial Augmented Multiomics Interface (Sami), which enables multiomics integration, high-dimensional clustering, spatial anatomical mapping of matched molecular features, and metabolic pathway enrichment. To demonstrate the utility of this approach, we applied Sami to evaluate metabolic diversity across distinct brain regions and to compare wild-type and Ps19 Alzheimer’s disease (AD) mouse models. Our findings reveal region-specific metabolic demands in the normal brain and highlight metabolic dysregulation in the Ps19 model, providing insights into the biochemical alterations associated with neurodegeneration.

11 March 2025 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
HCHarrison A. Clarke
Harrison A. Clarke
THTara R. Hawkinson
Tara R. Hawkinson
CSCameron J. Shedlock
Cameron J. Shedlock
TMTerrymar Medina
Terrymar Medina
RRRoberto A. Ribas
Roberto A. Ribas
RSramon sun
ramon sun

18 March 2025 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
XMXin Ma
Xin Ma
CSCameron J. Shedlock
Cameron J. Shedlock
TMTerrymar Medina
Terrymar Medina
RRRoberto A. Ribas
Roberto A. Ribas
HCHarrison A. Clarke
Harrison A. Clarke
RSramon sun
ramon sun

9 June 2026 in Nature Metabolism
Verified
Journal Article
Open access
THTara R. Hawkinson
Tara R. Hawkinson
ZLZizhen Liu
Zizhen Liu
RRRoberto A. Ribas
Roberto A. Ribas
TMTerrymar Medina
Terrymar Medina
RNRikke S. Nielsen
Rikke S. Nielsen
RSramon sun
ramon sun
Alzheimer's disease (AD) is a devastating neurodegenerative disorder marked by progressive cognitive decline. Metabolic disruptions are widely observed, yet their involvement in the molecular aetiology of AD remains underexplored. Here we identify hyperglycosylation as a driver of AD. Integrating spatial metabolomics, lipidomics and glycomics in transgenic AD mouse models and post-mortem human AD samples, along with advanced spatial isotopic tracing pulse-chase analysis of N-linked glycans, we demonstrate that the conserved phenotype of brain hyperglycosylation is driven by increased glycan biosynthesis. Genetic knockdown of glycan biosynthetic enzymes improves cognitive outcomes in AD mice whereas oral glucosamine supplementation impairs them. A retrospective analysis of electronic health records from patients with AD with varying disease severity shows that glucosamine supplementation is associated with accelerated AD progression and worsened survival. Overall, these results establish hyperglycosylation as a pathological driver of AD and highlight glycan metabolism as an actionable target in the fight against AD.

1 March 2026 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
XMXin Ma
Xin Ma
DADerek B Allison
Derek B Allison
JMJessica Macedo
Jessica Macedo
KBKayli Bolton
Kayli Bolton
HCHarrison Clarke
Harrison Clarke
LCLi Chen
Li Chen
Background: Gliomas are primary malignant brain tumors. Among them, grade IV astrocytomas represent the most aggressive form with limited treatment options and a poor prognosis. There is a critical need for reliable prognostic biomarkers to predict patient outcomes. Methods: In this study, we evaluated the prognostic roles of glycomics in predicting outcomes of patients with glioma. To address this need, we collected a cohort of 86 patients and conducted N-linked glycomics analysis using matrix-assisted laser desorption/ionization mass spectrometry on a tissue microarray comprising 78 gliomas and 8 controls. We performed survival analyses and machine-learning-based predictive modeling to evaluate the prognostic roles of glycomic features. Results and Conclusion: Glycomic features alone displayed strong performance in classifying mortality status, achieving a mean area under the receiver operating characteristic curve (AUROC) value of 0.880 and a mean area under the precision–recall curve (AUPRC) value of 0.925, and demonstrating consistent prognostic value in survival analyses with a mean concordance index of 0.759 across repeated cross-validation. Glycomic features also showed strong performance in predicting the incidence of seizure status, with a mean AUROC value of 0.778 and a mean AUPRC value of 0.766. Additionally, top-ranked glycans from machine-learning models can effectively stratify patients based on their survival outcomes, demonstrating their potential role as prognostic biomarkers.

3 September 2026 in Research Square
Verified
Preprint
Open access
PDF file
LCLi Chen
Li Chen
WJWeijia Jin
Weijia Jin
FZFengdi Zhao
Fengdi Zhao
XMXin Ma
Xin Ma
QLQing Lu
Qing Lu
RSramon sun
ramon sun
Understanding promoter-enhancer (PE) interactions is essential for elucidating gene regulation mechanisms. Although existing computational methods leverage DNA sequence to predict gene expression, many were developed primarily for bulk-level genomic data and emphasize predictive accuracy rather than regulatory inference. Here, we propose DeepCNet, a multimodal deep learning framework that predicts cell type-specific gene expression and infers cell type-specific PE interactions, enabling the construction of transcription factor gene regulatory networks (TF-GRNs) from single-cell multiome data. Evaluated on two single-cell multiome datasets from blood and brain tissues, DeepCNet consistently outperforms state-of-the-art methods in predicting cell type-specific gene expression. Importantly, PE interactions inferred by DeepCNet showed greater concordance with orthogonal chromatin interaction and CRISPR perturbation data than competing approaches. Analysis of cell type–specific GRNs identified TF hubs and highlighted both cell type–specific and shared regulatory programs. DeepCNet further extends to two-condition single-cell multiome studies, enabling the identification of differential PE interactions and characterization of TF-GRN alterations across conditions. As an illustrative application, we applied DeepCNet to single-cell multiome data from one Alzheimer's disease (AD) and one healthy control sample, identifying candidate differential PE interactions at AD risk loci and candidate TF hubs associated with AD-related pathways. Together, these results demonstrate the potential of DeepCNet to characterize transcriptional regulatory programs and cooperative TF interactions underlying cell type- and condition-specific gene expression.